To determine the efficacy of human relaxin-2 (hRLX2) in reversing radiationinduced bladder fibrosis and lower urinary tract dysfunction (LUTD). Radiation cystitis is a consequence of radiotherapy for pelvic malignancies. Acutely, irradiation leads to reactive oxygen/nitrogen species in urothelial cells, apoptosis, barrier disruption and inflammation. Chronically, this results in collagen deposition, bladder fibrosis and attenuated storage and voiding functions. In severe cases, cystectomies are performed as current therapies do not reverse fibrosis.
Introduction
Radiation cystitis. Radiation is a major intervention in treating pelvic organ malignancies. However, the risk for developing complications such as radiation cystitis limits the radiation dose 1 . The consequences of radiotherapy include a dose-dependent detrimental effect on normal organ function within the irradiated field 2 .
Chronic radiation cystitis can develop six to twelve months following radiotherapy with a prevalence of ~7% 3 . Consequences include vascular endothelial cell damage, inflammation, ischemia, collagen deposition and decreased bladder compliance 3 . A major feature of the chronic phase is mild to life-threatening hematuria 4 . Severely decreased bladder compliance due to collagen deposition can impair ureteric emptying causing renal dysfunction. Voiding failure can develop as the detrusor becomes progressively underactive and eventually acontractile. Ultimately the patient may require a cystectomy, to prevent renal failure and preserve some quality of life. Current therapies include anticholinergic agents for frequency and urgency, pain relief medications, cranberry juice capsules or instillation of hyaluronic acid and/or chondroitin sulfate which are symptomatic, invasive and often ineffective. Crucially, they do not reverse fibrosis to improve bladder compliance, and in theory could worsen it. There is currently no effective treatment to reverse bladder fibrosis, so it remains an unmet public health problem.
Contributing mechanisms of bladder fibrosis. The urinary bladder is composed of mucosa and muscular detrusor layers. The mucosa includes the urothelium and lamina propria; with the latter containing an extracellular matrix (ECM), composed of elastin, collagen-I and -III fibers. The ECM provides strength during contractions, high compliance during relaxation and low pressure storage of urine 5 . Collagen is continuously synthesized and degraded, but locally produced proinflammatory cytokines and other activators can impair this homeostatic balance by transforming fibroblasts to myofibroblasts to drive fibrosis 6 . Transforming growth factor beta-1 (TGF-β1) is implicated in the stimulation of membrane-cytoskeletal structural protein formation and in the synthesis of ECM through multiple signaling pathways 7 . TGF-β1 exerts ECMpreserving actions by suppressing matrix metalloproteinases (MMPs) activity and by inducing synthesis of protease inhibitors, such as tissue inhibitor of metalloproteinase (TIMP).
Relaxin hormone. Relaxin is a 6 kilodalton hormone first described in 1926 for inducing relaxation of uterine smooth muscle and softening of the pubic symphysis during pregnancy. However, this direct relaxation effect has only been observed on the uterine tissue of humans, pigs and rodents during pregnancy 8 . Non-pregnant pigs 9 and rats [10] [11] [12] must be pre-treated with high-dose estrogen for at least three days to induce direct relaxation of uterine smooth muscle. Direct relaxing effects of the hormone have not been reported for other smooth muscle including bladder. This 6 kilodalton hormone is also produced in the prostate and testes to enhance sperm motility 13 . It belongs to the insulin superfamily that includes relaxin-1 to -4 and insulinlike peptide-3 to -6. Peptides signal through four G-protein coupled receptors (RXFP1-4), with RXFP1 having the highest affinity for hRLX2 14 .
The differential effects of hRLX2 are mediated by at least three pathways where two are activated by the α-chain acting through RXFP1/2 and a third by the β-chain acting on RXFP1 ( Figure 1 ). The α-chain pathway elicits elevations of cAMP that enhance smooth muscle contractility through protein kinase A (PKA) inhibition of RhoA, which may also increase the expression of voltage-gated Ca 2+ channel currents 15 . The cAMP pathway is also involved in enhancement of proangiogenic signaling. The βchain is mediated through pERK1/2 and the cGMP pathway 16 .
RXFP1 activation by the β-chain increases phosphorylation of extracellular signal-regulated protein kinase 1 and 2 (pERK1/2) that enhances neuronal nitric oxide synthase (NOS) activity and cyclic guanosine monophosphate (cGMP) generation 14 .
Activation of this pathway disrupts profibrotic TGF-β/Smad2 phosphorylation (pSmad2) signaling 17 to inhibit collagen synthesis, promote expression of MMPs 18 and decrease expression of TIMPs 7 . RXFP1 may potentially prevent further inflammatory responses by directly inhibiting immune cell activation 19 .
The present study on the potential efficacy of relaxin in irradiation-induced fibroses in LUT organs was motivated by the published clinical findings on the antifibrotic properties of hRLX2 in acute heart failure 20 . Furthermore, neither the expression of RXFP receptors nor the effect of relaxin peptides in the LUT have been described. In this study, we utilized a mouse model of selective bladder irradiation to demonstrate the efficacy of hRLX2 in reversing the fibrotic consequences of chronic radiation cystitis.
Methods
Selective bladder irradiation. Adult female C57Bl/6 mice (6-18 weeks, Envigo labs) were anesthetized with 2,2-tribromoethanol (300 mg/kg, intraperitoneal) and a small incision was made into the lower abdominal wall to expose the bladder. A suture was tied to the urachus and mice placed sideways on a Lexan platform, allowing the organ to be externalized during irradiation (Figure 2A ). Bladders were catheterized with a FEP shield from a 24Ga BD angiocath, emptied and filled with 75 μl of saline for standardization. Mice were placed in an X-RAD 320 biological irradiator (Precision X-Ray) and the collimator and table height adjusted to focus the irradiation beam to ensure that only the bladder was irradiated. After delivery of a 10 Gy irradiation dose, the bladder was returned to the abdominal cavity, the incision sutured, and mice allowed to recover for up to 10 weeks. ALZET© osmotic pumps (model 1002) filled with saline (control) or recombinant hRLX2 (50 to 400 µg/kg/day) were implanted subcutaneously at the lower mid-region of the animal's back seven weeks post irradiation. Animals were used for experiments 15 days following implantation.
Urine spot assay. Mice were placed individually for 2 hours, between 11:00 am and 2:00 pm, in identical clean metabolic cages lined with Whatman filter paper. Food and water were withheld during this period. At the end, filter papers were collected for illumination with UV light and images retained as TIFF files for analysis with ImageJ software as reported previously 21 . Briefly, images were grayscaled, inverted, autothresholded using "Max entropy" method, converted to binary and "analyze particles" function used excluding particles smaller than 135 pixel 2 (< 0.5 μl). Calibration curve corresponding spot sizes to volumes was built based on known volumes of urine pipetted on the paper. Linear relation was confirmed with R 2 =0.9975, where volume [μl] = 0.0037 x spot size [pixel 2 ] (supplemental Figure 9 ).
Cystometrogram/electromyogram (CMG/EMG) recordings from decerebrate
mice. Mice were anesthetized using isoflurane (5% induction/2% maintenance in O2) and an incision made into the neck to expose the carotid arteries and the trachea.
Ligatures were placed around the carotid arteries to decrease cerebral blood flow and a tracheotomy was performed using PE-60 tubing connected to the anesthesia delivery system. A craniotomy was performed and the brain rostral to the supracollicular level sectioned away. Decerebration permits bladder cystometry without the use of anesthetics, which can modify reflex bladder contractions. A PE-50 catheter was inserted through the bladder dome, secured using a suture and connected to a pressure transducer and syringe pump. Two epoxy-coated, copper wire 50 μm EMG electrodes were inserted transperineally 1 mm lateral to the mid urethra to record from the EUS.
To perform voiding cystometry, the bladder was manually emptied and then filled with saline at 0.01 ml/min until reflex contractions were elicited. Bladder compliance was calculated as the volume infused into the bladder between two consequent contractions divided by the difference between pressure threshold and baseline pressure [μl/cmH2O]. Voided and residual volumes were estimated knowing the volume of saline infused.
Blood collection and assays of exogenously administered hRLX2 or endogenous mRLX1. Micro-hematocrit capillary tubes were used to collect 100-150 µl of blood from mouse tails. Tubes were centrifuged at 20,000 x g for 15 min to separate plasma from the cellular components. Plasma samples were rapidly frozen and stored at -80 °C until used for ELISA measurements of hRLX2 (R&D systems) or mRLX1 (LifeSpan BioScience).
In vitro measurement of passive and active contractile properties. Strips of bladder (8 mm by 1-2 mm) were obtained by cutting the bladder along the ventral midline. These were mounted in a temperature-controlled recording chamber 22 and connected to an isometric tension transducer and an anchor connected to a computercontrolled stepper motor to implement stretch protocols. Strips were superfused with a modified Tyrode's solution 23 and maintained at 36 ± 0.5°C. The baseline was stabilized and electrical field stimulation (EFS) with platinum electrodes (20 Hz, 3 sec train, 0.1 ms pulse width) was performed. Preparations were stretched incrementally to their optimal length (LO) at which peak EFS contractions are elicited 24 RT-qPCR. Tissues were harvested from four female mice and lysed using a bead homogenizer (MP FastPrep-24). Total RNA was extracted using an RNeasy mini kit (Qiagen) and used to generate cDNA using the iScript cDNA Synthesis Kit (Bio-Rad).
RT-qPCR was performed on a CFX Connect (Bio-Rad). Each PCR reaction was completed with 1.5 μL of cDNA using the TaqMan Fast Advanced Master Mix (Life Technologies). TaqMan probes were RXFP1 (Mm01220214_m1), RXFP2 (Mm01218503_m1), and reference gene HPRT (Mm00446968_m1). Expression levels were quantified using the 2 -ΔCt method.
Data and statistical analysis. Data from tension recordings were expressed as mean ± standard deviation from 'n' experiments. Force-frequency plots were fitted to
where T is the contraction magnitude, Tmax is the maximum tension at the highest frequency and f1/2 is the stimulation frequency at which Tmax/2 and n is a constant 23 . One-way ANOVA was used to determine between group differences and unpaired Student's t-tests determined differences between control vs. University.
Results
hRLX2 treatment restores normal bladder function in mice with chronic radiation cystitis. Since abdominal irradiation at the selected dose could be lethal (LD50 ≅ 8 Gy) 25 we developed a mouse model of chronic radiation cystitis by performing a laparotomy where the bladder is briefly exteriorized for selective high dose (10 Gy) irradiation ( Figure 2A ). hRLX2 did not significantly affect the voiding function of nonirradiated mice ( Figure 2C ). Cystometry performed nine weeks post irradiation demonstrated a loss of the micturition response and exhibited overflow incontinence as shown in Figure 2D .
Respective external urethral sphincter electromyogram (EUS-EMG, green traces) demonstrated that animals had prolonged guarding reflexes and that normal phasic bursting activity as seen in Figure 2B did not occur. However, when hRLX2 was administered (400 µg/kg/day) for two weeks in 7 week post-irradiated animals, the CMGs and EUS-EMGs ( Figure 2E ) became similar to those seen in nonirradiated mice ( Figure 2B ) with the return of a normalized guarding reflex and bursting (Figure 2E with isolated bladder strips. In length-tension studies, there was a marked increase in passive tension of irradiated mouse bladders (i.e., decrease in tissue compliance) which was evident by four weeks post irradiation and peaked by six to nine weeks ( Figure 4A ).
There was no significant difference at time points up to 16 weeks post exposure (not shown). Moreover, the increased passive tension in irradiated bladders was also revealed by measurements performed with 5 mM EDTA-Tyrode's solution (Ca 2+ free) ( Figure 4B ), further supporting that increased ECM deposition alone alters relaxation properties of the bladder wall. In chronic radiation cystitis, the decreased contractility and compliance were reversed by a two weeks treatment with hRLX2 (400 µg/kg/day) with experimental recordings becoming comparable to those of nonirradiated mouse bladders ( Figure 4C ). Furthermore, hRLX2 treatment increased active force generation even beyond that of nonirradiated controls ( Figure 4D ). There was a significant increase in contractions evoked by electrical field stimulation (20 Hz) in hRLX2 treated preparations. Contractions evoked by muscarinic agonist, oxotremorine-M, and high KCl were not significantly different between groups. Additionally, there was increased expression of detrusor Cav1.2 ( Figure 4F ), the primary Cav1.2α1C subunit that encodes for the L-type Ca 2+ channel, responsible for detrusor contraction.
Urothelial loss and bladder collagen deposition in chronic radiation cystitis contribute to LUT dysfunction. Bladder sections stained with Van Gieson solution
showed urothelial layer disruption, increased collagen content (intense pink staining) and significant muscle damage nine weeks post injury ( Figure 4H ) compared to age matched controls ( Figure 4G ). In contrast, mice receiving hRLX2 treatment showed a return of the urothelial layer and normal collagen and smooth muscle architecture ( Figure 4I ) that is indifferent from nonirradiated controls. Quantification of collagen to total tissue area ratio showed a significant increase in collagen content of irradiated mouse bladders which was reversed by hRLX2 treatment to a level comparable to nonirradiated controls ( Figure 4J ).
The hRLX2 receptors, RXFP1 and RXFP2 are expressed in mouse bladders.
Immunofluorescence analysis of normal female mouse bladder sections demonstrates that the receptors for hRLX2, RXFP1/2 are expressed in the detrusor layer, with RXFP2 being the dominant subtype ( Figure 5A and B, green -RXFP, red -smooth muscle actin, blue -DAPI nuclear stain, Figure 5C -negative control without the primary antibody). Confirmation of immunofluorescence findings by Western blot analysis ( Figure 5D ) supports that there is direct action of hRLX2 on bladder smooth muscle and, possibly, myofibroblasts in the mouse bladder -positive controls for RXFP1 and RXFP2 in uterus and prostate are also shown. Expression of RXFP1 and RXFP2 in the bladder was also demonstrated by RT-qPCR, with expression in detrusor higher than in mucosa ( Figure 5E ).
Measurements of endogenous and exogenously administered relaxin in mouse
plasma. Supplemental Figure 10 shows our data on the: 1) measurements of endogenous mouse relaxin-1 (mRLX1; the homologue to hRLX2) plasma levels in control male, female and pregnant mice; 2) continuous subcutaneous infusion of hRLX2 produced a dose-dependent increase in plasma levels of hRLX2. The plasma levels of hRLX2 measured in the mouse group receiving 50 µg/kg/day were equivalent to the levels of hRLX2 in human pregnancy 27 and mRLX1 detected at day 10 of gestation.
Chronic infusion at 400 µg/kg/day by day 7 raised the plasma levels to 17.5 ng/mL in non-pregnant female mice, which is approximately 10 times higher than E10 pregnant mice 27 . These levels were stable for the rest of the treatment period (up to 14 days).
Discussion
Fibrosis has been implicated as a central mechanism in a wide variety of pathologies including LUT dysfunction secondary to chronic inflammation that leads to urinary retention 2,3 . This has a substantial effect on the quality of life and has severe health implications including the potential for development of progressive renal dysfunction. As such, patients may need to use intermittent self-catheterization and, in severe cases, undergo a cystectomy, as there are presently no effective therapies that reverse fibrosis. Anti-fibrotic therapy would have clear benefits not only in radiation cystitis, but also in other fibrosis-driven bladder dysfunctions, including neurogenic bladder and outlet obstruction.
The present study leveraged the findings of earlier reports to investigate the therapeutic benefits from sustained infusion of exogenous hRLX2 in a diseased mouse model without deleting endogenous relaxin. We found that subcutaneous infusion of Therefore, we choose the regimen of chronic administration for the present study. From previous reports, 400 μg/kg/day was the minimum dose needed to prevent and reduce fibrosis in various models 29 . hRLX2 may also prevent recurrent inflammation potentially via inhibition of immune cell activation 30 . We propose that hRLX2 acts via G-protein coupled RXFP1/2, causing transient elevations of cAMP and cGMP, via a NOS dependent pathway, activation of kinases and transcription factors that lead to anti-inflammatory, vasodilatory, anti-oxidative and antifibrotic properties to reverse fibrosis ( Figure 1C ).
The high active tension in hRLX2 treated irradiated mice compared to control suggests that hRLX2 likely shifts the increased nitric oxide (NO) signaling in irradiated mice away from the proapoptotic/profibrotic pathway towards NO-dependent/cGMP signaling, which promotes collagen degrading gelatinase activity. The contractile strength of detrusor smooth muscles is further increased as indicated by the increased EFS responses that may result from genomic changes in the expression of Cav1.2 31 .
Conclusion
These studies, although pre-clinical with transferability to the human system yet to be determined, demonstrate the therapeutic potential of hRLX2 in treating LUT pathologies due to radiation cystitis. Relaxin is a natural hormone which has passed human safety tests in clinical trials, increases Cav1.2 expression to improve detrusor contractility, arrests collagen deposition and reverses fibrosis to increase bladder compliance. 
